Evidence map›Paper›PMID 28968735›Full record

Trial reportRheumatology (Oxford, England)2017

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

Iain B McInnes, Philip J Mease, Christopher T Ritchlin, Proton Rahman, Alice B Gottlieb, Bruce Kirkham, Radhika Kajekar, Eumorphia-Maria Delicha, Luminita Pricop, Shephard Mpofu

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Rheumatology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01752634 phase3completednot on this map

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2013 to 2019Enrolled397ConditionsPsoriatic ArthritisArmsSecukinumab (AIN457), Placebo
NCT04261010 nacompletednot on this mapstarted 2020, after this paper: background citation

TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium

TypeinterventionalSponsorCliniques universitaires Saint-Luc- Université Catholique de LouvainRan2020 to 2023Enrolled36ConditionsPsoriatic ArthritisArmsGlobal/single cell gene expression profiles obtained from Synovial biopsies
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. La Tunisie medicale · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iain B McInnesInstitute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Philip J MeaseDivision of Rheumatology Clinical Research, Swedish Medical Centre and University of Washington, Seattle, WA.
Christopher T RitchlinAllergy/Immunology and Rheumatology Division, University of Rochester, Rochester, NY, USA.
Proton RahmanFaculty of Medicine, Memorial University, St. John's, NL, Canada.
Alice B GottliebDepartment of Dermatology, New York Medical College, Valhalla, NY, USA.
Bruce KirkhamRheumatology Department, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Radhika KajekarNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Eumorphia-Maria DelichaNovartis Pharma, Basel, Switzerland.
Luminita PricopNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Shephard MpofuNovartis Pharma, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods: Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2, 3 and 4 and every 4 weeks thereafter. Placebo-treated patients were re-randomized to receive secukinumab 300 or 150 mg s.c. from week 16 (placebo non-responders) or week 24 (placebo responders). Exploratory endpoints at week 104 included 20, 50 and 70% improvement in ACR criteria (ACR20, 50, 70); 75 and 90% improvement in the Psoriasis Area Severity Index, 28-joint DAS with CRP, presence of dactylitis and enthesitis and other patient-reported outcomes. For binary variables, missing values were imputed; continuous variables were analysed by a mixed-effects model for repeated measures. Results: A total of 86/100 (86%), 76/100 (76%) and 65/99 (66%) patients in the secukinumab 300, 150 and 75 mg groups, respectively, completed 104 weeks. At week 104, ACR20 response rates after multiple imputation in the 300, 150 and 75 mg groups were 69.4, 64.4 and 50.3%, respectively. Sustained clinical improvements were observed through week 104 with secukinumab across other clinically important domains of PsA. Responses were sustained through week 104 regardless of prior anti-TNF-α use. Over the entire treatment period the incidence, type and severity of adverse events were consistent with those reported previously. Conclusion: Secukinumab provided sustained improvements in signs and symptoms and multiple clinical domains in patients of active PsA through 2 years of therapy. Secukinumab was well tolerated, with a safety profile consistent with that reported previously. Trial registration: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01752634.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticC-Reactive ProteinDiarrheaDouble-Blind MethodDrug Therapy, CombinationGlucocorticoidsHumansLogistic ModelsLongitudinal StudiesMethotrexateNasopharyngitisPatient Reported Outcome MeasuresQuality of LifeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsC-Reactive ProteinGlucocorticoidsMethotrexatesecukinumabanti-TNF therapybiological therapiesefficacyinterleukinjointslong termpsoriatic arthritissafetyspondyloarthritisswelling

Identifiers

PMID28968735
PMCPMC5850284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.